Apixaban for Prevention of Acute Ischemic Events 2 - APPRAISE-2

Description:

Apixaban is a novel oral anti Xa antagonist, with demonstrated safety and efficacy, as compared with agents such as warfarin in patients with atrial fibrillation and enoxaparin in patients undergoing orthopedic surgery. The phase II APPRAISE-1 trial noted that in patients with recent acute coronary syndrome (ACS), apixaban, in the background of dual antiplatelet therapy with aspirin and clopidogrel, was associated with reduced ischemic events, but increased bleeding, especially with doses hig...